A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies

Phase 1 Completed 30 enrolled CASI pharmaceuticals, Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The main objectives of this study are to evaluate the side effects of MKC-1 and to determine a safe dose of MKC-1 for future studies in patients with hematological malignancies

Timeline

Start: 2006-11
Primary completion: 2009-01
Completion: 2009-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MKC-1	Small molecule	30 mg	—
Subject	MKC-1	Small molecule	100 mg	—

A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies

Summary

Timeline

Drugs

Indications